Literature DB >> 31722002

FLT3 inhibitors added to induction therapy induce deeper remissions.

Mark Levis1, Wenge Shi2, Ken Chang3, Christian Laing2, Reinhold Pollner2, Christopher Gocke1, Emily Adams1, Flora Berisha3, Jelveh Lameh2, Arnaud Lesegretain3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31722002     DOI： 10.1182/blood.2019002180

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

Review 1.  Gilteritinib: potent targeting of FLT3 mutations in AML.

Authors:  Mark Levis; Alexander E Perl
Journal:  Blood Adv       Date:  2020-03-24

2.  Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.

Authors:  Richard A Larson; Sumithra J Mandrekar; Lucas J Huebner; Ben L Sanford; Kristina Laumann; Susan Geyer; Clara D Bloomfield; Christian Thiede; Thomas W Prior; Konstanze Döhner; Guido Marcucci; Maria Teresa Voso; Rebecca B Klisovic; Ilene Galinsky; Andrew H Wei; Jorge Sierra; Miguel A Sanz; Joseph M Brandwein; Theo de Witte; Dietger Niederwieser; Frederick R Appelbaum; Bruno C Medeiros; Martin S Tallman; Jürgen Krauter; Richard F Schlenk; Arnold Ganser; Hubert Serve; Gerhard Ehninger; Sergio Amadori; Insa Gathmann; Hartmut Döhner; Richard M Stone
Journal:  Leukemia       Date:  2021-03-02       Impact factor: 11.528

Review 3.  Potential targeting of FLT3 acute myeloid leukemia.

Authors:  Alexander J Ambinder; Mark Levis
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

Review 4.  Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia.

Authors:  Andreas Burchert
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

Review 5.  FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation.

Authors:  Amanda Blackmon; Ibrahim Aldoss; Brian J Ball
Journal:  Blood Lymphat Cancer       Date:  2022-09-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.